OBJECTIVES: The fused in sarcoma (FUS) protein is a 526 amino acid and its expression is ubiquitous. Recently, mutations in a gene coding FUS have been identified in familial amyotrophic lateral sclerosis (ALS). Also, FUS has been found in neuronal cytoplasmic inclusions in sporadic forms of ALS, suggesting that FUS has an important role in the neurodegeneration occurring in sporadic disease. However, there has been no study of FUS in ALS skin. MATERIAL AND METHODS: We made a quantitative immunohistochemical study of the expression of FUS in the skin from patients with sporadic ALS and controls. RESULTS: The proportion of FUS-immunoreactive (ir) cells in the epidermis in ALS patients was significantly higher (P < 0.001) than in controls. There was a significant positive relationship (r = 0.78, P < 0.001) between the proportion and duration of illness in ALS patients. The optical density of FUS-ir cells in the epidermis in ALS patients is markedly stronger (P < 0.001) than in controls. There was a significant positive relation (r = 0.49, P < 0.05) between the immunoreactivity and duration of illness in ALS patients. CONCLUSIONS: These data suggest that changes of FUS in ALS skin are related to the disease process, and that metabolic alterations of FUS may take place in the skin of patients with ALS.
OBJECTIVES: The fused in sarcoma (FUS) protein is a 526 amino acid and its expression is ubiquitous. Recently, mutations in a gene coding FUS have been identified in familial amyotrophic lateral sclerosis (ALS). Also, FUS has been found in neuronal cytoplasmic inclusions in sporadic forms of ALS, suggesting that FUS has an important role in the neurodegeneration occurring in sporadic disease. However, there has been no study of FUS in ALS skin. MATERIAL AND METHODS: We made a quantitative immunohistochemical study of the expression of FUS in the skin from patients with sporadic ALS and controls. RESULTS: The proportion of FUS-immunoreactive (ir) cells in the epidermis in ALSpatients was significantly higher (P < 0.001) than in controls. There was a significant positive relationship (r = 0.78, P < 0.001) between the proportion and duration of illness in ALSpatients. The optical density of FUS-ir cells in the epidermis in ALSpatients is markedly stronger (P < 0.001) than in controls. There was a significant positive relation (r = 0.49, P < 0.05) between the immunoreactivity and duration of illness in ALSpatients. CONCLUSIONS: These data suggest that changes of FUS in ALS skin are related to the disease process, and that metabolic alterations of FUS may take place in the skin of patients with ALS.
Authors: Shu Yang; Katharine Y Zhang; Ruvini Kariawasam; Monique Bax; Jennifer A Fifita; Lezanne Ooi; Justin J Yerbury; Garth A Nicholson; Ian P Blair Journal: Neurotox Res Date: 2015-05-27 Impact factor: 3.911
Authors: Shingo Kariya; Jacinda B Sampson; Lesley E Northrop; Christopher M Luccarelli; Ali B Naini; Diane B Re; Michio Hirano; Hiroshi Mitsumoto Journal: Amyotroph Lateral Scler Frontotemporal Degener Date: 2014-05-09 Impact factor: 4.092
Authors: Kathryne Kirk; Chris Gennings; Jonathan C Hupf; Saba Tadesse; Marilena D'Aurelio; Hibiki Kawamata; Federica Valsecchi; Hiroshi Mitsumoto; Giovanni Manfredi Journal: Ann Neurol Date: 2014-08-21 Impact factor: 10.422
Authors: Csaba Konrad; Hibiki Kawamata; Kirsten G Bredvik; Andrea J Arreguin; Steven A Cajamarca; Jonathan C Hupf; John M Ravits; Timothy M Miller; Nicholas J Maragakis; Chadwick M Hales; Jonathan D Glass; Steven Gross; Hiroshi Mitsumoto; Giovanni Manfredi Journal: Mol Neurodegener Date: 2017-10-24 Impact factor: 14.195